UMODL1

Summary

UMODL1 (uromodulin like 1, HGNC:12560) is a protein-coding gene on chromosome 21q22.3, encoding Uromodulin-like 1 (Q5DID0).

Predicted to enable calcium ion binding activity and peptidase inhibitor activity. Predicted to act upstream of or within several processes, including cellular response to gonadotropin-releasing hormone; regulation of granulosa cell apoptotic process; and regulation of ovarian follicle development. Predicted to be located in cytoplasm; external side of plasma membrane; and extracellular region. Predicted to be active in cell surface and extracellular space.

Source: NCBI Gene 89766 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 341 total
• MANE Select transcript: NM_001004416

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12560
Approved symbol	UMODL1
Name	uromodulin like 1
Location	21q22.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000177398
Ensembl biotype	protein_coding
OMIM	613859
Entrez	89766

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 6 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined, 4 protein_coding

ENST00000400421, ENST00000400423, ENST00000400424, ENST00000400427, ENST00000408910, ENST00000408989, ENST00000466434, ENST00000468982, ENST00000475047, ENST00000484174, ENST00000484712, ENST00000485357, ENST00000491559, ENST00000497243

RefSeq mRNA: 4 — MANE Select: NM_001004416 NM_001004416, NM_001199527, NM_001199528, NM_173568

CCDS: CCDS42935, CCDS42936, CCDS56214, CCDS56215

Canonical transcript exons

ENST00000408910 — 23 exons

Exon	Start	End
ENSE00001577541	42115873	42115985
ENSE00001578165	42110880	42111121
ENSE00001581041	42109562	42109699
ENSE00001581966	42119111	42119324
ENSE00001583142	42111506	42111710
ENSE00001584873	42103868	42104087
ENSE00001586354	42085291	42085412
ENSE00002470797	42071317	42071392
ENSE00002518687	42084084	42084245
ENSE00003465097	42113573	42113830
ENSE00003474859	42127672	42127831
ENSE00003498478	42102166	42102278
ENSE00003522321	42137439	42137641
ENSE00003525841	42098926	42099180
ENSE00003528559	42122831	42123150
ENSE00003585837	42088294	42088480
ENSE00003587798	42121087	42121224
ENSE00003600545	42129713	42129797
ENSE00003635733	42126345	42126490
ENSE00003647204	42076005	42076247
ENSE00003668611	42090298	42090438
ENSE00003668796	42127006	42127242
ENSE00003916518	42142096	42142996

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 80.40.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6360 / max 35.3792, expressed in 125 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
189273	0.3127	89
189272	0.2843	93
189277	0.0272	11
189275	0.0063	1
189274	0.0028	1
189276	0.0027	3

Top tissues by expression

235 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	80.40	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.09	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.72	silver quality
secondary oocyte	CL:0000655	74.20	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	64.12	gold quality
left testis	UBERON:0004533	61.69	gold quality
testis	UBERON:0000473	59.78	gold quality
right testis	UBERON:0004534	58.61	gold quality
right lung	UBERON:0002167	58.45	gold quality
oviduct epithelium	UBERON:0004804	58.03	gold quality
fallopian tube	UBERON:0003889	56.44	gold quality
oocyte	CL:0000023	55.66	gold quality
nucleus accumbens	UBERON:0001882	53.66	gold quality
prefrontal cortex	UBERON:0000451	52.78	gold quality
caudate nucleus	UBERON:0001873	52.57	gold quality
nasal cavity mucosa	UBERON:0001826	51.95	gold quality
right frontal lobe	UBERON:0002810	51.92	gold quality
calcaneal tendon	UBERON:0003701	51.81	gold quality
Brodmann (1909) area 9	UBERON:0013540	51.36	gold quality
primary visual cortex	UBERON:0002436	51.33	gold quality
putamen	UBERON:0001874	50.74	gold quality
frontal cortex	UBERON:0001870	50.03	gold quality
bone marrow cell	CL:0002092	49.79	gold quality
amygdala	UBERON:0001876	49.77	gold quality
mucosa of transverse colon	UBERON:0004991	49.73	gold quality
sperm	CL:0000019	49.44	silver quality
neocortex	UBERON:0001950	49.31	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	49.27	gold quality
hindlimb stylopod muscle	UBERON:0004252	48.75	gold quality
occipital lobe	UBERON:0002021	48.44	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.36
E-GEOD-100618	no	560.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting UMODL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-363-5P	99.46	64.51	1015
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-4506	99.34	67.47	526
HSA-MIR-1228-3P	99.00	66.53	857
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-4289	98.26	66.90	810
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-5585-5P	97.95	68.80	1024
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-4653-5P	97.22	67.72	1429
HSA-MIR-2682-3P	97.10	66.16	840
HSA-MIR-410-5P	96.55	66.28	459
HSA-MIR-323B-5P	96.12	66.39	472
HSA-MIR-494-5P	95.31	66.29	463

Literature-anchored findings (GeneRIF, showing 3)

• Data report the isolation of a novel gene, designated UMODL1, similar to uromodulin (UMOD)/Tamm-Horsfall glycoprotein, on human chromosome 21q22.3. (PMID:15194491)
• result suggests that rs283971 is located in the frequent recombinant region on the UMODL1, and that this region might play a critical role in disease susceptibility to high myopia. (PMID:18535602)
• It was shown that common UMODL1 polymorphisms are unlikely to be important in the genetic susceptibility to high myopia in Han Chinese. (PMID:22857148)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	umodl1	ENSDARG00000068923
mus_musculus	Umodl1	ENSMUSG00000054134
rattus_norvegicus	Umodl1	ENSRNOG00000001157

Paralogs (5): TECTB (ENSG00000119913), OIT3 (ENSG00000138315), UMOD (ENSG00000169344), GP2 (ENSG00000169347), ZPLD1 (ENSG00000170044)

Protein

Protein identifiers

Uromodulin-like 1 — Q5DID0 (reviewed: Q5DID0)

Alternative names: Olfactorin

All UniProt accessions (7): Q5DID0, H0Y3S4, H0Y856, H0Y880, H0Y887, H0Y898, H0Y8E5

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cell membrane Cytoplasm Cytoplasm.

Tissue specificity. Isoform 4 is expressed at low level in kidney, testis and fetal thymus. Isoform 3 is expressed at low level in prostate, testis and fetal thymus.

Isoforms (4)

UniProt ID	Names	Canonical?
Q5DID0-1	1	yes
Q5DID0-2	2
Q5DID0-3	3, UMOLD1S
Q5DID0-4	4, UMOLD1L

RefSeq proteins (4): NP_001004416, NP_001186456, NP_001186457, NP_775839 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000082	SEA_dom	Domain
IPR000152	EGF-type_Asp/Asn_hydroxyl_site	PTM
IPR000742	EGF	Domain
IPR001507	ZP_dom	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR003961	FN3_dom	Domain
IPR008197	WAP_dom	Domain
IPR009030	Growth_fac_rcpt_cys_sf	Homologous_superfamily
IPR011489	EMI_domain	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR036116	FN3_sf	Homologous_superfamily
IPR036645	Elafin-like_sf	Homologous_superfamily
IPR042235	ZP-C_dom	Homologous_superfamily
IPR048290	ZP_chr	Domain
IPR049883	NOTCH1_EGF-like	Domain
IPR055355	ZP-C	Domain
IPR055356	ZP-N	Domain

Pfam: PF00095, PF00100, PF01390, PF07645, PF23344

UniProt features (54 total): sequence variant 16, domain 10, glycosylation site 10, disulfide bond 9, region of interest 2, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5DID0-F1	69.69	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (9): 37–94, 61–70, 93–104, 511–525, 519–534, 536–551, 901–914, 908–923, 1157–1215

Glycosylation sites (10): 89, 109, 172, 322, 335, 417, 585, 713, 984, 1050

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 74 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOCC_CELL_SURFACE, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_OVARIAN_FOLLICLE_DEVELOPMENT, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_FEMALE_SEX_DIFFERENTIATION, GOBP_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_HORMONE, GOBP_SEX_DIFFERENTIATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_CONNECTIVE_TISSUE_DEVELOPMENT, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP

GO Biological Process (8): single fertilization (GO:0007338), regulation of gene expression (GO:0010468), adipose tissue development (GO:0060612), cellular response to gonadotropin-releasing hormone (GO:0097211), regulation of granulosa cell apoptotic process (GO:1904708), regulation of ovarian follicle development (GO:2000354), regulation of apoptotic process (GO:0042981), regulation of developmental process (GO:0050793)

GO Molecular Function (3): calcium ion binding (GO:0005509), peptidase inhibitor activity (GO:0030414), protein binding (GO:0005515)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), cytoplasm (GO:0005737), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), extracellular region (GO:0005576), plasma membrane (GO:0005886), membrane (GO:0016020), cell periphery (GO:0071944)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
fertilization	1
gene expression	1
regulation of macromolecule biosynthetic process	1
animal organ development	1
connective tissue development	1
cellular response to peptide hormone stimulus	1
response to gonadotropin-releasing hormone	1
regulation of epithelial cell apoptotic process	1
granulosa cell apoptotic process	1
ovarian follicle development	1
regulation of developmental process	1
apoptotic process	1
regulation of programmed cell death	1
developmental process	1
regulation of biological process	1
metal ion binding	1
enzyme inhibitor activity	1
peptidase activity	1
peptidase regulator activity	1
binding	1
intracellular anatomical structure	1
plasma membrane	1
cell surface	1
side of membrane	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

762 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UMODL1	LIPI	Q6XZB0	542
UMODL1	MSLNL	Q96KJ4	507
UMODL1	UBASH3A	P57075	506
UMODL1	AXDND1	Q5T1B0	484
UMODL1	HSF2BP	O75031	480
UMODL1	FAM13C	Q8NE31	472
UMODL1	KRTAP10-10	P60014	471
UMODL1	PRMT2	P55345	446
UMODL1	TFF3	Q07654	438
UMODL1	UNCX	A6NJT0	427
UMODL1	TMPRSS3	P57727	418
UMODL1	SDAD1	Q9NVU7	414
UMODL1	LHFPL7	Q6ICI0	402
UMODL1	RRP1B	Q14684	396
UMODL1	OR1N2	Q8NGR9	396

IntAct

2 interactions, top by confidence:

A	B	Type	Score
UMODL1	C2CD2L	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): DNAJB5 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), APAF1 (Affinity Capture-MS), MAP3K7 (Affinity Capture-MS), C2CD2L (Affinity Capture-MS), TYW1 (Affinity Capture-MS), C15orf39 (Affinity Capture-MS), PKMYT1 (Affinity Capture-MS), SNX3 (Affinity Capture-MS), ANKLE2 (Affinity Capture-MS), THAP11 (Affinity Capture-MS), FNDC3A (Affinity Capture-MS), SND1 (Cross-Linking-MS (XL-MS)), UMODL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LHF2, D3YX43, D3YZF7, O08852, O14931, O15533, O43157, O70394, O70540, O75074, O88204, P01880, P0C788, P18627, P59383, P61484, P70289, Q15109, Q28173, Q5BK54, Q5DID0, Q5RKR3, Q5TJE4, Q61790, Q61826, Q62151, Q63495, Q64612, Q6PZD2, Q7TQH7, Q7Z4F1, Q80W87, Q86T13, Q86VR7, Q8C310, Q8CB67, Q8CJH3, Q8IZF5, Q8MJ02, Q8N441

Diamond homologs: O08524, P54097, Q12836, Q5DID0, Q5DID3, Q96PL2, Q9BH11, Q9D733, O08523, O75443, P07911, P19218, P25291, P27590, P48733, P55259, Q5R5C1, Q6DFV8, Q862Z3, Q8N2E2, Q8R4V5, Q91X17, Q9YH85, Q8CH34, Q07929, P35555, P48834, P98133, Q61554, Q9TV36, P20239, P47984, Q05996

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

341 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	276
Likely benign	42
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

4169 predictions. Top by Δscore:

Variant	Effect	Δscore
21:42085286:T:TA	acceptor_gain	1.0000
21:42085289:A:AG	acceptor_gain	1.0000
21:42085290:G:GA	acceptor_gain	1.0000
21:42085290:GC:G	acceptor_gain	1.0000
21:42085290:GCT:G	acceptor_gain	1.0000
21:42085290:GCTC:G	acceptor_gain	1.0000
21:42085290:GCTCC:G	acceptor_gain	1.0000
21:42088289:CACA:C	acceptor_loss	1.0000
21:42088291:CAGGT:C	acceptor_loss	1.0000
21:42088292:AGGTC:A	acceptor_loss	1.0000
21:42088293:G:GC	acceptor_loss	1.0000
21:42099181:G:GG	donor_gain	1.0000
21:42102161:CTCA:C	acceptor_loss	1.0000
21:42102165:GAT:G	acceptor_gain	1.0000
21:42109556:T:TA	acceptor_gain	1.0000
21:42109663:G:T	donor_gain	1.0000
21:42109698:GG:G	donor_gain	1.0000
21:42109698:GGGT:G	donor_loss	1.0000
21:42109699:GG:G	donor_gain	1.0000
21:42109700:GTA:G	donor_loss	1.0000
21:42109701:T:G	donor_loss	1.0000
21:42119106:CGCAG:C	acceptor_loss	1.0000
21:42119107:GCA:G	acceptor_loss	1.0000
21:42119108:CAGG:C	acceptor_loss	1.0000
21:42119110:G:T	acceptor_loss	1.0000
21:42119110:GGT:G	acceptor_gain	1.0000
21:42119110:GGTGC:G	acceptor_gain	1.0000
21:42119246:G:GT	donor_gain	1.0000
21:42119294:G:GT	donor_gain	1.0000
21:42119323:GG:G	donor_gain	1.0000

AlphaMissense

8593 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
21:42127181:T:C	C1157R	0.998
21:42127181:T:A	C1157S	0.996
21:42127182:G:C	C1157S	0.996
21:42127183:C:G	C1157W	0.996
21:42127784:T:C	C1215R	0.995
21:42127786:C:G	C1215W	0.995
21:42123123:G:C	W1040C	0.994
21:42123123:G:T	W1040C	0.994
21:42127182:G:A	C1157Y	0.994
21:42127748:T:C	F1203L	0.994
21:42127750:T:A	F1203L	0.994
21:42127750:T:G	F1203L	0.994
21:42127785:G:A	C1215Y	0.994
21:42123130:T:A	C1043S	0.993
21:42123131:G:C	C1043S	0.993
21:42127779:T:C	L1213P	0.993
21:42127784:T:A	C1215S	0.993
21:42127785:G:C	C1215S	0.993
21:42126438:T:A	C1081S	0.992
21:42126439:G:C	C1081S	0.992
21:42126445:T:G	F1083C	0.992
21:42127186:G:C	W1158C	0.992
21:42127186:G:T	W1158C	0.992
21:42127187:G:C	A1159P	0.992
21:42127673:T:A	C1178S	0.992
21:42127674:G:C	C1178S	0.992
21:42127823:T:C	C1228R	0.992
21:42123020:T:G	F1006C	0.991
21:42123130:T:C	C1043R	0.991
21:42127230:T:C	F1173S	0.991

dbSNP variants (sampled 300 via entrez): RS1000037125 (21:42082009 G>A), RS1000093229 (21:42067225 C>A), RS1000093824 (21:42132526 T>C), RS1000100580 (21:42115531 T>C), RS1000214438 (21:42112904 T>C), RS1000241312 (21:42076600 G>A), RS1000256596 (21:42090828 G>A), RS1000298896 (21:42080394 C>T), RS1000309371 (21:42112690 A>C), RS1000337546 (21:42137971 A>G), RS1000370291 (21:42138110 C>G), RS1000387668 (21:42085178 G>A), RS1000397050 (21:42106525 G>A), RS1000465483 (21:42066940 A>C,G,T), RS1000472901 (21:42115273 A>G)

Disease associations

OMIM: gene MIM:613859 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001762_602	Obesity-related traits	4.000000e-07
GCST003918_1	Idiopathic osteonecrosis of the femoral head	2.000000e-07
GCST007267_181	Systolic blood pressure	2.000000e-09
GCST008362_129	Birth weight	4.000000e-11
GCST90002388_590	Lymphocyte count	5.000000e-14
GCST90002389_431	Lymphocyte percentage of white cells	3.000000e-14
GCST90026413_16	Severe insulin-deficient type 2 diabetes	2.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:1001930	idiopathic osteonecrosis of the femoral head
EFO:0006335	systolic blood pressure
EFO:0004344	birth weight
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation	2
propionaldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Catechin	affects cotreatment, increases expression	1
Dactinomycin	increases expression, affects cotreatment	1
Estradiol	increases expression	1
Lipopolysaccharides	decreases expression, affects cotreatment	1
Malathion	increases expression	1
Methapyrilene	increases methylation	1
Methylcholanthrene	affects binding, increases reaction	1
Ozone	affects expression, increases abundance	1
Smoke	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases methylation, increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer